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SUMMARY
To unravel the normal vasculature transcriptome and determine how it is altered by neighboring ma-
lignant cells, we compared gene expression patterns of endothelial cells derived from the blood ves-
sels of eight normal resting tissues, five tumors, and regenerating liver. Organ-specific endothelial
genes were readily identified, including 27 from brain. We also identified 25 transcripts overex-
pressed in tumor versus normal endothelium, including 13 that were not found in the angiogenic
endothelium of regenerating liver. Most of the shared angiogenesis genes have expected roles in
cell-cycle control, but those specific for tumor endothelium were primarily cell surface molecules
of uncertain function. These studies reveal striking differences between physiological and patholog-
ical angiogenesis potentially important for the development of tumor-specific, vascular-targeted
therapies.INTRODUCTION
Angiogenesis is required for the progression of many dis-
eases, including age-related macular degeneration and
cancer (Kerbel and Folkman, 2002; Ferrara and Kerbel,
2005). Inhibiting or destroying abnormal blood vessels
associated with cancer and other diseases using either
antiangiogenic agents or vascular disrupting agents has
become a major therapeutic strategy. However, angio-
genesis is also required for normal physiological pro-
cesses, such as corpus luteum formation in the ovary
and endometrial regeneration during the menstrual cycle.
Current targets of antiangiogenic therapy, such as VEGF,
are thought to be critical for both physiological and path-
ological angiogenesis, and clinical side effects of anti-
VEGF therapy are beginning to emerge. Cross-reactivity
with normal tissues is even more of a concern for the de-
velopment of vascular disrupting agents, i.e., cytotoxicdrugs that target newly formed blood vessels. Thus,
markers that can separate physiological and pathological
angiogenesis are urgently needed in order to selectively
deliver antiangiogenic or vascular disrupting agents to
diseased tissues, minimizing the potential for side ef-
fects. In an attempt to identify targets on the endothelial
cells (ECs) that line tumor blood vessels, we previously
compared gene expression patterns in ECs derived
from either normal or malignant colorectal tissues. These
studies led to the identification of 46 tumor endothelial
markers, called TEMs (St. Croix et al., 2000). Further
studies on a subset of these (TEM1–TEM9) revealed
that each of them, with the possible exception of
TEM8, are also elevated in the vessels of the corpus lu-
teum during physiological angiogenesis (St. Croix et al.,
2000; Nanda et al., 2004). The identification of TEM8
suggests that markers with an expression pattern more
restricted to tumor vessels may exist. However, whichSIGNIFICANCE
Angiogenesis is critical for the progression of many diseases, including age-related macular degeneration and
cancer. Markers that can separate physiological and pathological angiogenesis are urgently needed in order to
selectively deliver antiangiogenic or vascular disrupting agents to diseased tissues, minimizing the potential for
side effects. By comparing the vascular transcriptome of normal resting, normal proliferating, and malignant tis-
sues, we have identified several genes that are selectively overexpressed on blood vessels during tumor angio-
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unanswered questions.
What factorsmight influence gene expression during tu-
mor angiogenesis but not normal physiological angiogen-
esis? Many tumor-associated environmental and bio-
chemical factors are known to affect gene expression.
For example, cytokine-producing inflammatory cells,
such as macrophages, are a common feature of tumors
but are rarely found in the corpus luteum when angiogen-
esis is maximal (Goede et al., 1999). Hypoxia, tumor-de-
rived growth factors, and changes in blood flow can also
affect gene expression. In this study, we set out to identify
molecular markers that can differentiate pathological and
physiological angiogenesis. In order to generate a model
of physiological angiogenesis that could be readily con-
trolled in a homogeneous genetic background, we took
advantage of the fact that following 70% partial hepatec-
tomy, the murine liver regenerates its mass over a period
of 4 days, a process requiring angiogenesis (Michalopou-
los and DeFrances, 1997; Drixler et al., 2002). We then de-
veloped methods to isolate ECs from isogenic normal
adult livers, regenerating livers, and tumor-bearing livers.
In an attempt to identify genes that are the most broadly
expressed among tumors of various origins but are either
absent or expressed at relatively low levels in all normal
vessels, we also developed techniques to isolate ECs
from multiple normal and tumor tissue types. We system-
atically compared gene expression profiles among the
multiple samples by performing serial analysis of gene
expression (SAGE) on the isolated ECs, an unbiased tech-
nique that can be used even when cell numbers are
limited. These studies demonstrate the existence of multi-
ple organ-specific endothelial transcripts aswell as a num-
ber of genes that are selectively overexpressed in the
vessels of tumors. Further analysis of the top cell surface
tumor endothelial marker identified, CD276, revealed that,
in humans, this cell surface receptor is overexpressed
during pathological, but not physiological, angiogenesis.
By unraveling the endothelial transcriptome, we have re-
vealed the identity of several markers highly restricted to
specific anatomical sites, including tumors, a finding
which has significant implications for the development of
the most selective vascular targeted therapies.
RESULTS
To begin to unravel the mouse endothelial transcriptome,
we set out to develop a method that could be used to im-
munopurify ECs from a variety of tissue types. Immuno-
purification is difficult because the ECs are enmeshed in
a complex tissue containing an extracellular matrix of vari-
able composition and multiple nonendothelial cell types.
Our initial attempts to purify ECs involved antibody recog-
nition of CD31, the conventional cell surface marker used
for affinity purification of mouse ECs. However, this
marker proved to be suboptimal because of its cross-re-
activity with hematopoietic cells (data not shown). Instead,
we found that CD105 (endoglin) and/or VE-cadherin spe-
cifically localized to the ECs of normal and tumor tissues.
540 Cancer Cell 11, 539–554, June 2007 ª2007 Elsevier Inc.For example, both anti-CD105 and anti-VE-cadherin anti-
bodies specifically labeled ECs in heart, but CD105 was
amore suitable marker in liver because antibodies against
this surface receptor appeared to stain all the endothelium
including sinusoidal ECs (Figures 1A and 1B) whereas
anti-VE-cadherin antibodies did not (data not shown).
The cell isolation strategy involved tissue dissociation,
the removal of non-ECs, and, finally, the positive selection
of ECs using magnetic beads coupled to either anti-VE-
cadherin or anti-CD105 antibodies, the choice depending
on the tissue being dissociated (see Experimental Proce-
dures for details). To assess the purity of the isolated cells,
we generated cDNA from either whole tissues or purified
ECs and then performed quantitative reverse transcription
polymerase chain reaction (QPCR). These studies re-
vealed a marked enrichment of endothelial-specific genes
such as VE-cadherin in each of the purified fractions com-
pared to unfractionated whole tissues (Figure 1C) but little
contamination by hematopoietic cells as judged by CD45
expression (B.S.C., unpublished data). Subsequent gene
expression analysis (see below) confirmed the purity of
the cells.
To begin to unravel the normal endothelial transcrip-
tome, we performed longSAGE on ECs isolated from
brain, heart, kidney, lung, muscle, spleen, and liver. These
SAGE libraries utilize a 21 nucleotide ‘‘long tag’’ which fa-
cilitates the mapping of genes directly to genomic DNA
even when EST or cDNA sequence is unavailable (Saha
et al., 2002). In total, 700,189 tags were obtained from
these 7 normal EC libraries (see Table S1 in the Supple-
mental Data available with this article online). An initial
analysis of the SAGE data immediately revealed the
expression of multiple transcripts that are known to be
selectively expressed in endothelial cells including VE-
cadherin, VEGFR2, von Willebrand Factor, CD31, CD105,
and claudin 5. In contrast, markers of epithelial, hemato-
poietic, hepatocyte, and other potential contaminating
cell types were absent or rare (Table S2).
To determine if we could identify organ-specific endo-
thelial transcripts, we began by searching for brain endo-
thelial markers (BEMs) defined as genes that were ex-
pressed 20-fold or higher in brain compared to all other
normal endothelium (Table 1). The most abundant and dif-
ferentially expressed gene identified was the brain glu-
cose transporter Slc2a1 (Glut-1), a blood-brain barrier
(BBB) marker previously found to be expressed on the lu-
minal surface of brain endothelium (Pardridge et al., 1990;
Farrell and Pardridge, 1991). Importantly, 13 of the 27
BEMs (50%) identified are predicted to reside at the
cell surface, and at least 9 of these are transporters poten-
tially involved in BBB function. Seven of the BEMs, includ-
ing five cell surface transporters, were previously localized
to brain endothelium by in situ staining, thus validating the
SAGE data we obtained (for references see Table 1).
Some of the cell surface transporters have also been de-
tected in liver tissues where they appear to be expressed
predominantly by hepatocytes or other non-ECs, consis-
tent with their absence from our liver EC SAGE libraries
(Gu et al., 2000; Konig et al., 2000; Mesli et al., 2004).
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The Endothelial TranscriptomeFigure 1. Purification of ECs from Normal and Malignant Tissues
(A) Immunofluorescence staining of heart tissue demonstrated colocalization of CD105 (green) with VE-cadherin (red) in the vessels. Scale bar, 20 mm.
(B) Immunofluorescence staining of liver tissue with CD105 (green). Scale bar, 20 mm.
(C) A QPCR analysis was used to assess the purity of the EC preparations. QPCR analysis was performed on cDNA generated directly from unfrac-
tionated normal whole tissues (WT) or frompurified ECs isolated from normal tissues (N-ECs) or the tumors (T-ECs) indicated. The endothelial-specific
transcript VE-cadherin was enriched 110- to 530-fold in the endothelial fractions. The modest level of VE-cadherin found in the unfractionated heart
and lung sample is presumably due to a higher proportion of ECs in these tissues. In this experiment, gene expression was normalized to that of Eif4h,
a gene found to be uniformly expressed in all cells as assessed by SAGE (Velculescu et al., 1999). Unfractionated brain was used to calibrate relative
expression because this tissue had the lowest VE-cadherin expression levels.
(D) Model used to identify genes expressed during pathological, but not physiological, angiogenesis. ECs were isolated from normal resting livers,
regenerating livers, or tumor bearing livers.We also identified intracellular enzymes, such as glutathi-
one-S-transferase a 4 (Gsta4), which could potentially be
involved in protecting the brain from toxic chemicals that
enter the blood.
We next identified genes that were overexpressed in
liver endothelium, which we called liver endothelial
markers (LEMs) (Table 1). The most highly expressed
gene was deoxyribonuclease 1-like 3, a recently identified
nuclease that may be involved with chromatin clearance
from the circulation (Napirei et al., 2005). The best charac-
terized gene identified was CD32, a low-affinity Fc g-re-
ceptor that is a known marker of liver sinusoidal ECs
(Muro et al., 1993).We also identified two lectin-like recep-
tors, one of which was shown recently to be expressed
predominantly by sinusoidal ECs of human liver and lymph
node (Liu et al., 2004). Seven of the LEMs identified are
predicted to reside at the cell surface, including three
that have not yet been characterized. These results clearly
highlight the complexity of blood vessels and demonstrate
the existence of multiple organ-specific endothelial
markers in different tissues.
Next, in order to identify genes that were elevated dur-
ing physiological angiogenesis, ECs were isolated from
liver 24, 48, or 72 hr following partial hepatectomy, the
period during which EC division is thought to occur (Mi-
chalopoulos and DeFrances, 1997). In total, we isolated395,234 SAGE tags from regenerating liver (Table S1).
We then compared gene expression patterns of regener-
ating liver ECs with a combined set of EC libraries derived
from all nonproliferating normal organs including resting
liver (Figure 1D). This comparison revealed 12 genes that
were overexpressed in regenerating liver ECs compared
to nonangiogenic ECs (Table 2), which we refer to as an-
giogenesis endothelial markers (AEMs). At least seven of
these genes are thought to be involved in regulating pro-
gression through the cell cycle, consistent with the fact
that these ECs are dividing. For example, the most abun-
dant AEM is an ubiquitin-conjugating enzyme, Ube2c. Its
human counterpart, UBE2C (UBCH10), has been shown
to be important for progression through the G1 phase of
the cell cycle (Townsley et al., 1997; Rape and Kirschner,
2004). Protein regulator of cytokinesis 1 (PRC1) is amitotic
spindle-associated CDK substrate that is required for cy-
tokinesis (Jiang et al., 1998). Ckap2 and Cks2 have also
been shown to regulate cell cycle (Spruck et al., 2003;
Tsuchihara et al., 2005), and DNA topoisomerase II-a
(Top2a), thymidine kinase 1 (TK1), and the Ki-67 antigen
have been used as markers of proliferating cells for more
than two decades (Bradshaw, 1983; Gerdes et al., 1984;
Sampson et al., 1992). We also identified one extracellular
matrix glycoprotein, tenascin C, that has been frequently
associated with angiogenesis of malignant tumors,Cancer Cell 11, 539–554, June 2007 ª2007 Elsevier Inc. 541
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The Endothelial TranscriptomeTable 1. SAGE Tags Elevated Specifically in Brain Endothelium or Liver Endothelium
Brain Heart Kidney Liver Lung Muscle Spleen Accession Numbers Descriptionb
BEMs
1 754 8 1 2 1 12 4 NM_011400 GLUT-1a (Pardridge et al., 1990;
Farrell and Pardridge, 1991)
2 157 0 0 0 0 1 0 NM_030687 Organic anion transporter 2a
(Gao et al., 2000)
3 93 0 1 0 0 1 1 NM_008973 Pleiotrophin (Yeh et al., 1998)
4 32 0 0 0 0 0 0 NM_009728 ATPase, class V, type 10Aa
5 40 0 0 0 1 0 0 NM_009402 Peptidoglycan recognition protein 1
6 26 0 0 0 0 0 0 NM_021471 Organic anion transp. 14a
(Tohyama et al., 2004)
7 29 0 0 0 0 0 0 NM_008239 Forkhead box Q1
8 19 0 0 0 0 0 0 NM_031194 Organic anion transporter 3a
(Mori et al., 2003; Ohtsuki et al., 2004)
9 73 0 0 0 3 0 0 NM_172479 SN2, Solute carrier family 38,member
5a
10 40 0 0 0 1 2 0 NM_172471 Interalpha (globulin) inhibitor H5
11 12 0 0 0 0 0 0 NM_010703 Lymphoid enhancer binding factor 1
12 23 0 0 0 0 0 1 NM_011404 Slc7a5 aa transportera (Kageyama
et al., 2000)
13 20 1 0 0 0 0 0 NM_023805 Solute carrier family 38, member 3a
14 17 0 0 0 0 0 0 NM_009574 Zinc finger protein of the cerebellum 2
15 81 6 0 0 1 3 0 NM_052994 Testican-2 (Schnepp et al., 2005)
16 26 0 1 0 1 1 0 NM_008256 3-HMG-CoA synthase 2
17 15 0 0 0 0 0 0 NM_028748 Progestin and adipoQ receptor family
member V
18 68 0 1 2 1 0 1 AK172004 APC downregulated 1, Drapc1
19 13 0 0 1 0 0 0 NM_027096 Unknownc, GDPD
phosphodiesterase family
20 26 0 0 3 1 0 0 NM_029001 Unknownc, putative transmembrane
protein
21 19 1 0 0 0 1 0 NM_027299 DES2, lipid desaturase/ C4-
hydroxylase
22 39 0 1 0 2 0 1 XM_486083 Unknownc, kelch repeat and BTB
(POZ) domain
23 46 2 1 0 1 1 0 NM_017405 Lipolysis stimulated receptora
24 36 2 0 0 1 1 0 NM_010357 Glutathione S-transferase, alpha 4a
25 9 0 0 0 1 0 0 NM_013869 TNF receptor superfamily, member
19
26 17 1 0 0 0 1 0 NM_011532 T-box 1
27 6 0 0 0 1 0 0 XM_620023 Unknownc, putative transmembrane
protein
LEMs
1 0 0 0 196 0 0 0 NM_007870 Deoxyribonuclease 1-like 3
2 0 0 0 58 0 0 3 NM_010959 LZP, oncoprotein induced
transcript 3
3 0 0 0 16 0 0 0 NM_023438 Unknownc, putative transmembrane
protein542 Cancer Cell 11, 539–554, June 2007 ª2007 Elsevier Inc.
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Brain Heart Kidney Liver Lung Muscle Spleen Accession Numbers Descriptionb
4 1 0 0 123 0 0 6 AK150613 CD32 (Muro et al., 1993)
5 0 1 0 33 0 1 1 NM_033616 Unknownc, putative G-protein
coupled receptor
6 0 1 0 14 0 0 0 NM_019985 C-type lectin-like receptor 2
7 0 0 0 216 0 0 24 NM_029465 Clec4g (LSECtin) (Liu et al., 2004)
8 0 1 0 42 2 1 0 NM_018797 Plexin C1
9 0 1 0 9 0 0 0 NM_011719 Wnt9B
10 1 0 0 16 1 0 0 AK144596 Unknown
11 0 1 0 9 0 0 0 NM_008092 GATA-binding protein 4 (Dame et al.,
2004)
12 0 0 0 10 1 2 0 AB049755 MBL-associated serine protease-3
13 0 0 0 5 0 0 1 NM_023132 Renin binding protein
14 0 0 0 16 1 2 1 NM_144830 Unknownc, putative transmembrane
protein
15 1 0 1 11 0 0 0 NM_011243 Retinoic acid receptor, beta
The 27 genes which displayed more than 20-fold expression in brain endothelium compared to the six other normal endothelial
libraries shown are listed in descending order. Likewise, 14 genes were found to be expressed at levels 20-fold higher in liver en-
dothelium compared to the other normal endothelial libraries. To calculate tag ratios, we assigned a value of 0.5 in caseswhere zero
tags were observed. Tag numbers for each group were normalized to 100,000 transcripts except for kidney which was normalized
to 30,000 tags due to the small number of tags obtained for that particular tissue (Table S1). The tag sequences corresponding to
the genes shown can be found in Tables S4 and S5. Genbank accession numbers and a description of the gene product corre-
sponding to each tag are given.
aGene product has either a putative or established role in BBB function.
bGenes previously shown to be expressed in either brain or liver endothelium are followed by the associated references.
c Uncharacterized gene with structural domains indicated.inflamed tissues, and healing wounds (Zagzag et al., 1996;
Tanaka et al., 2004). The only AEM identified encoding
apredicted cell surfaceproductwas integrin b3, a receptor
that partners with integrin av and is thought to regulate an-
giogenesis (Brooks et al., 1994).
In nonangiogenic endothelial libraries, SAGE tag counts
for AEMs were often not observed, making the absolute
level of expression of these transcripts in normal resting
ECs unclear (Table 2). Therefore, to accurately determine
relative expression levels and validate these genes using
a more sensitive technique, we performed QPCR. In order
to carefully evaluate gene expression kinetics following
angiogenic stimulation, we evaluated expression of
AEMs in ECs isolated at 6, 18, 40, 72, and 96 hr post-par-
tial hepatectomy. For comparison, we also analyzed ECs
isolated from each of seven normal tissues including
brain, heart, intestine, kidney, liver, lung, and spleen (Table
S3). All of the EC samples used for QPCR were derived
from fresh EC isolations independent of those used to
generate the initial SAGE libraries. The QPCR analysis
confirmed that each of the AEMs were induced in the re-
generating liver ECs with peak levels ranging from 15- to
100-fold over nonproliferating ECs (Figure 2A). All of the
AEM genes identified were also overexpressed in tumor
endothelial cells (see below), providing further evidence
that expression of these genes is upregulated during an-
giogenesis. Although most of the genes displayed maxi-mum mRNA expression at 72 hr, the genes encoding in-
hibin-b B and integrin b3 reached their peak expression
levels by 6 hr. Such early endothelial response genes
may be important upstream regulators of the angiogenic
cascade.
Finally, in order to identify genes that were elevated only
during pathological angiogenesis but not physiological
angiogenesis in a controlled setting, we isolated ECs
from tumors that were grown in the liver (Figure 1D). For
these studies, we employed two metastatic colon cancer
cell lines, CT26 and KM12SM, because this tumor type
typically metastasizes to the liver. For comparison, we
also isolated ECs from three different tumor types grown
subcutaneously: SW620, LLC, and EMT6. We chose co-
lon, lung, and mammary carcinomas because they repre-
sent three of the most prevalent tumor types in humans.
SW620 and KM12SM are of human origin and were grown
as tumor xenographs in immune-deficient mice, whereas
CT26, EMT6, and LLC are ofmurine origin andwere grown
as syngeneic tumor graphs in immune-competent mice. A
summary of the cell lines employed and the host strains
used for endothelial purification can be found in Table S1.
In total, 592,610 SAGE tags were isolated from tumor
ECs. Again, RT-PCR analysis and an evaluation of the
SAGE tags for various cell-specific markers confirmed
that the isolated cells were predominantly of endothelial
origin (see Figure 1C and Table S2). A comparison of the
Cancer Cell 11, 539–554, June 2007 ª2007 Elsevier Inc. 543
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Normal Resting ECs RL ECs Tumor ECs
Brain Heart Kidney Liver Lung Muscle Spleen 24 hr 48 hr 72 hr CT26 EMT KM LLC SW
Accession
Numbers Descriptionc
AEMs
0 0 0 0 0 0 0 0 10 14 5 3 4 9 0 NM_026785 Ube2ca
0 0 0 0 0 0 0 1 5 11 0 5 2 3 2 NM_026412 TRAF4af1
0 0 0 1 1 0 0 0 17 16 5 8 3 11 10 NM_011623 DNA topo IIaa
0 0 0 0 0 0 0 0 4 3 3 2 2 8 0 NM_001004140 Ckap2a
1 1 0 1 0 2 0 19 11 3 31 28 14 20 11 NM_008381 Inhibin beta-B
0 0 0 1 0 0 0 0 4 6 5 6 5 5 7 NM_025415 Cks2a
1 0 0 1 0 0 0 4 13 12 7 6 1 8 5 NM_009387 TK1a
0 0 0 0 1 2 0 0 2 6 5 14 16 24 12 NM_011607 Tenascin C
0 3 0 0 0 0 0 5 3 3 5 5 3 9 1 NM_024435 Neurotensin
0 0 0 1 1 0 0 0 5 10 5 3 4 10 0 NM_145150 Prc1a
0 0 0 0 1 1 2 0 11 12 7 7 2 5 4 XM_133912 Ki67 antigena
0 1 0 1 0 1 1 3 5 3 17 10 6 4 9 NM_016780 Integrin-b3b
TEMs
0 0 0 0 1 0 0 1 1 1 7 11 0 26 4 DQ832275 Vscp
0 1 0 0 0 0 0 0 1 0 1 6 3 10 16 DQ832276 CD276b
(B7-H3)
0 0 0 0 1 0 0 0 0 1 6 4 5 9 12 DQ832277 ETSvg4
(Pea3)
0 1 0 0 0 0 0 0 0 0 8 2 1 26 3 DQ832278d CD137b
(4-1BB)
0 2 1 0 0 0 1 0 0 0 15 5 19 8 37 DQ832280 MiRP2b
0 0 0 0 0 0 0 0 0 0 3 5 0 2 1 NM_023137 Ubiquitin D
(FAT10)
0 0 0 0 0 1 1 0 0 0 1 3 0 17 5 DQ832281 Doppelb
(Prion-PLP)
0 0 1 0 1 0 0 0 0 0 0 6 2 7 7 DQ832282 Apelin
1 1 1 0 0 0 0 0 0 0 2 10 4 5 7 NM_008827 Plgf
0 1 0 0 1 0 0 0 0 0 14 1 1 5 0 DQ832283 Ptprnb (IA-2)
0 0 1 0 0 0 0 1 0 1 0 6 3 7 1 DQ832284 CD109b
1 0 0 0 0 0 0 2 1 0 10 1 1 5 1 DQ832285 Ankylosisb
0 0 1 0 1 0 0 1 0 0 3 2 8 1 5 NM_007739 Coll. VIII, a1
The top 12 AEM genes with the highest tag ratios are listed in descending order. Tags from regenerating liver (RL) ECs and tumor
endothelial cells were combined and compared to the total tags derived from the seven normal endothelial libraries shown. In the
bottom panel, the top 13 TEM genes with the highest tag ratios in tumor ECs compared to all nontumor endothelial libraries are
shown. To calculate tag ratios, a value of 0.5 was assigned in cases where zero tags were observed. Tag numbers for each group
were normalized to 100,000 transcripts except for kidney which was normalized to 30,000 tags due to the lower number of tags
obtained for that particular tissue (Table S1). The gene product corresponding to each tag is given, followed by alternative names
in parentheses. Genbank accession numbers and the gene name or symbol corresponding to each tag is given. Tag sequences
corresponding to the genes shown can be found in Table S6 (AEMs) or Table S7 (TEMs).
aGenes encoding products thought to be important in cell-cycle control.
b Encodes known or predicted cell surface protein.
cGene name is given followed by alternative names in parentheses.
d The Genbank accession number for the secreted variant sCD137 is DQ832279.544 Cancer Cell 11, 539–554, June 2007 ª2007 Elsevier Inc.
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regenerating liver, revealed 13 genes that were that were
at least 10-fold overexpressed in the endothelium of tu-
mors (Table 2). Analysis of the cDNA and EST databases
revealed multiple splice variants for many of these genes.
In order to identify which sequences and splice variants
were expressed in tumor endothelium we sequenced 10
of the 13 genes using tumor endothelial cDNA (for acces-
sion numbers, see Table 2). The most differentially ex-
pressed transcript was a previously uncharacterized
gene that encodes a putative cytoplasmic protein contain-
ing an SH2 domain. This gene, which we called vascular
SH2-containing protein (Vscp), was overexpressed 11-
to 110-fold in tumor endothelium.
In total, 7 of the 12 genes were found to encode cell sur-
face receptors. The most differentially expressed of these
was CD276, followed by CD137 (Tnfrsf9, 4-1bb). Se-
quencing of CD137 revealed two products expressed in
tumor ECs, one encoding the full-lengthmembrane bound
form, and another containing a variant that lacks the sixth
exon encoding the transmembrane domain. This form,
which we call sCD137, is presumably secreted and repre-
sents the mouse counterpart of the previously identified
human sCD137 (Michel et al., 1998).
In order to validate the expression pattern of the TEMs
identified by SAGE using a more sensitive technique,
again we performed QPCR on our panel of normal and tu-
mor ECs. Each of the newly identified tumor endothelial
genes had a pattern of expression that was strikingly sim-
ilar to that predicted by the SAGE data, with highest levels
in tumor ECs and much lower levels in regenerating liver
ECs similar to that observed in nonproliferating normal
endothelium (Figure 2B). Most of the genes were overex-
pressed in the ECs of all of the tumors examined, although
six of the genes (ankylosis, apelin, MiRP2, CD109, doppel,
and ubiquitin D) appeared to be overexpressed in the ves-
sels of only a subset of the tumor types. One of these,
ubiquitin D, was only expressed in the vessels of mouse
tumors (CT26, EMT6, and LLC), which we reasoned could
potentially have been derived from contamination of the
EC preparations with tumors cells. However, by RT-PCR
analysis ubiquitin D mRNA was essentially undetectable
in cultured tumor cell lines or tumor cell-enriched fractions
prepared from tumor samples (Figure S1), suggesting
that this was an unlikely explanation for the expression
patterns observed.
To exclude the possibility that the differentially ex-
pressed transcripts were derived from other contaminat-
ing non-ECs, we performedmRNA in situ hybridization us-
ing a highly sensitive nonradioactive technique. First, we
tested the top four brain endothelial markers and found
each was localized to ECs throughout the brain whereas
expression in liver was undetectable (Figure 3 and Table
S8). Similarly, an analysis of five of the top LEMs revealed
that each was readily detectable in liver endothelium but
not brain endothelium. LEMs were expressed predomi-
nantly in the sinusoidal ECs with a pattern of staining sim-
ilar to that of the endothelial control VEGFR2 (see Figure 3
and Table S8). However, LEM5, a previously uncharacter-ized putative G protein coupled receptor, was also found
in the larger vessels of central veins, portal veins, and
hepatic arteries.
We also evaluated 9 of the top tumor endothelial
markers identified, and found each of them to be ex-
pressed in the ECs of various tumor types (Figures 4A
and 4B). Importantly, for each of these TEMs, staining
was undetectable in the endothelium of normal adult brain
and liver tissues (Figure 4A and data not shown). However,
mRNA in these control tissues was considered intact be-
cause LEMs, BEMs, and pan-endothelial controls such
as CD31 and VEGFR2 were readily detected in these tis-
sues. The positive signals observed for TEMs in tumor en-
dothelium were considered specific because their pat-
terns matched those observed with endothelial control
probes and omission of the antisense riboprobes or sub-
stitution with a sense control resulted in a loss of signal
in each case (data not shown). These data clearly demon-
strate that these newly identified TEMs are expressed pre-
dominantly by tumor vessels.
The therapeutic potential of the genes identified will
largely depend on whether or not the patterns of gene ex-
pression found in mice are recapitulated in humans and
whether protein expression patterns followmRNA expres-
sion patterns. One of the newly identified tumor endothe-
lial markers, CD137, was recently found to be overex-
pressed in the vessels of a variety of human tumors and
at sites of inflammation (Broll et al., 2001; Drenkard
et al., 2007). Using antibodies against CD137, we were
able to validate the overexpression of CD137 protein in ly-
sates of human colorectal cancer compared to patient-
matched normal colonic mucosa (see Figure S2). To begin
addressing the expression pattern of additional TEMs in
humans, we decided to focus on CD276 because it was
the most differentially expressed cell surface receptor
identified by our SAGE analysis, and antibodies that spe-
cifically recognize humanCD276 protein have recently be-
come available. First, we generated riboprobes against
human CD276 and performed mRNA in situ hybridization
on normal and malignant colorectal tissues. As shown in
Figure 4C,CD276mRNAwasmost prominent in the tumor
vessels, with a pattern of expression similar to that of the
endothelial control VEGFR2. Unexpectedly, CD276 ex-
pression was also detected in the tumor cells themselves,
albeit at a lower level. In contrast, CD276 expression was
undetectable in normal colonic mucosa, and an analysis
of the tumor margin showed a striking on/off pattern of
stainingat the tumor/normal border (Figure4C, rightpanel).
Next, we sought to evaluate CD276 protein expression
patterns using anti-CD276 antibodies. We began by as-
sessing the overall level of CD276 in extracts taken from
12 normal and 12malignant colorectal tissues, 10 of which
were patient-matched. CD276 was clearly elevated in 11
of the 12 tumors, while the remaining matched normal/
tumor pair (case P7) displayed unaltered expression (Fig-
ure 5A). We also evaluated CD276 expression levels in six
lung tumors, and comparison with patient-matched con-
trols revealed increased expression in each of the cases
(Figure 5B). All tumor samples appeared to overexpress
Cancer Cell 11, 539–554, June 2007 ª2007 Elsevier Inc. 545
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overexpression of this form in transfected 293 cells re-
sulted in a product of similar size (Figure 5A).
To determine the cellular source of this upregulated pro-
tein and expand our analysis of tumors, we performed an
immunohistochemical survey of various human tumor
types including colon, lung, breast, esophageal, and blad-
der cancer. First, we analyzed paraffin sections taken from
ten patient-matched samples of normal colonic mucosa
and colorectal cancer or ten patient-matched samples
of non-small-cell lung cancer along with adjacent normal
lung tissue. All samples represented different cases than
those used for immunoblotting. Staining with an anti-
CD276 polyclonal antibody revealed a vessel-like pattern
in all cases of human colorectal or lung cancer analyzed,
but not in matched normal tissues (Figures 5C–5H and
Table S9). Moreover, this vessel-like pattern of staining
was also observed in each of a smaller number of breast,
esophageal, and bladder cancers, but not in correspond-
ing normal tissues (Figures 5I–5L). Similar expression
patternswere observed using an independentmonoclonal
antibody (data not shown). Interestingly, again CD276
overexpression was frequently detected in the tumor cells
while normal epithelium was uniformly negative. The high-
est tumor cell expression levels of CD276 were found in
lung and breast cancer where they appeared to match
that found in tumor endothelium (Figures 5F, 5G, and 5L).
To ensure that the antibodies were predominantly stain-
ing endothelial cells, colocalization studies were per-
formed on six additional cases of normal or malignant
colorectal tissues. In each case, we observed clear coloc-
alization of CD276 protein with vWF, a classic endothelial
marker (Figure 6A). Although the tumor vessels stained
most intensely, again the tumor cells themselves appeared
positive, while all cell types from normal colonic mucosa
were negative. Next, we stained human corpus luteum to
determine if the normal angiogenic vessels of this tissue
express CD276. Unlike the vWF control, CD276 expres-
sion was not detected in these angiogenic vessels (Fig-
ure 6B). These studies demonstrate that CD276 is consis-
tently overexpressed at the protein level in the blood
vessels of various human cancers and may therefore rep-
resent a useful target for tumor-specific vascular targeting.
DISCUSSION
In order to gain a more comprehensive understanding of
the endothelial transcriptome, we generated a gene ex-
pression database for ECs isolated from a panel of normal
and malignant tissues. In total, we generated a data setof 1.7 million endothelial SAGE tags, almost 10-fold
deeper than our original endothelial data set (St. Croix
et al., 2000). The large set of normal tissues proved valu-
able not only for identifying ‘‘tissue-specific’’ endothelial
markers, but also for substantially limiting the number of
tumor endothelial markers identified to those that were
the least likely to share cross-reactivity with normal endo-
thelium. Indeed, this point is readily apparent when the
newSAGE libraries are specifically queried for TEMswhich
were identified in previous studies conducted on a single
tissue type, i.e., normal and malignant human colorectal
tissues (St. Croix et al., 2000). Four of the genes identified
in those studies, TEM1, TEM5, TEM7, and TEM8, encode
cell surface proteins and are of particular interest as poten-
tial vascular targets. The mouse ortholog of one of these
genes,Tem7, did not appear tobeoverexpressed in the tu-
mor endothelial libraries of our new SAGE database or
when analyzed by QPCR (S.S. and B.S.C., unpublished
data) consistent with previous mRNA in situ hybridization
studies conducted on tumors in mice (Carson-Walter
et al., 2001). Given that mice and humans diverged during
evolution over 65 million years ago, it is not surprising that
the cross-species expression patterns of certain genes do
not always match one another. However, genes that are
coordinately expressed have an obvious advantage for
translational studies due to the immediate availability of
appropriatemodels for preclinical testing of new therapeu-
tic agents that target tumor vasculature. An analysis of the
new SAGE data for Tem1, Tem5, and Tem8 did reveal
overexpression of these genes in mouse tumor endothe-
lium. However, these 3 TEMs were excluded from the final
list of angiogenic markers presented in this study because
of similarly high expression in the ECs of one or more nor-
mal adult tissues. For example, Tem1 expression was un-
expectedly found in normal kidneyECs,Tem5 in brain ECs,
andTem8 in lungECs (data not shown). Thus, identification
of the most specific genes that are the least likely to share
cross-reactivity with other tissues is greatly facilitated by
the use of multiple normal tissues controls.
These studies also demonstrate that normal ECs from
different anatomical sites can be readily distinguished
based upon their unique gene expression signatures.
Brain endothelium, for example, expressed a large num-
ber of unique cell surface transporters, several of which
have already been implicated in BBB function. We also
identified several previously uncharacterized cell surface
transporters likely to have a role in maintaining the BBB.
Liver endothelium also demonstrated a distinctive gene
expression pattern. Such organ-specific endothelial
markers hold much promise for the selective delivery of
molecular medicine to targeted anatomical sites.Figure 2. Gene Expression in Resting Normal ECs, Regenerating Liver ECs, and Tumor ECs
(A) Expression of AEMs is upregulated in regenerating liver ECs. Note the high expression levels of integrinß3 and inhibin-bB only 6 hr following partial
hepatectomy. For comparison, expression patterns of a BEM (Organic-anion-transporter 2, Oatp2) are also shown in the upper left panel.
(B) Expression of TEMs is upregulated in tumor ECs. Note the low basal expression of these genes in regenerating liver ECs similar to that observed in
ECs of normal resting tissues. Gene expression was evaluated by real-timeQPCR and comparedwith that ofSrnp70, a gene found to be expressed at
nearly identical levels in all ECs by SAGE. For AEMs and TEMs, the results are expressed as a ratio between the gene of interest and Srnp70 and are
normalized to the average expression of all nonangiogenic normal ECs. For Oatp2, samples were normalized to the average expression in intestinal,
heart and kidney ECs. For comparison, normal ECs from resting liver (time = 0 hr) were grouped with the regenerating liver ECs.Cancer Cell 11, 539–554, June 2007 ª2007 Elsevier Inc. 547
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esis have been known to be morphologically distinct (Sa-
saki et al., 1991). However, the extent of differential gene
Figure 3. LEM and BEM Genes Identified by SAGE Are
Expressed by ECs In Vivo
Localization of mRNA in ECs (red stain) is demonstrated for the brain
endothelial markers GLUT-1 (BEM1) and organic anion transporter 2
(BEM2), and the liver endothelial markers deoxyribonuclease 1-like 3
(LEM1) and oncogene induced transcript 3 (LEM2). Note that the
BEMs are selectively expressed in brain endothelium whereas the
LEMs are selectively expressed in liver endothelium. The endothelial
control probe, VEGFR2, stains both brain and liver endothelium. Stain-
ing of LEMs is most prominent in the sinusoidal endothelium, wherein
the nuclear body appears to stain most intensely. A dilute counterstain
was applied to the sections to highlight the lack of detectable expres-
sion in the non-ECs of the tissues. Scale bars, 50 mM
548 Cancer Cell 11, 539–554, June 2007 ª2007 Elsevier Inc.expression between these cellular states has remained
elusive. Most of the well-studied molecules that are
thought to regulate tumor angiogenesis such as VEGF,
bFGF, the angiopoietins, and their receptors also regulate
normal physiological angiogenesis. One notable excep-
tion is placental growth factor, one of the tumor-restricted
endothelial markers identified in this study that was previ-
ously found to be important for pathological angiogenesis
but not developmental angiogenesis using Plgf-knockout
mice (Carmeliet et al., 2001). Although all genes expressed
in tumor endothelium are expected to have some normal
physiological function, they may not be expressed in all
types of angiogenesis, or at the same developmental
stage. Analogous to ‘‘oncofetal antigens’’ (Wepsic,
1983), some of the tumor endothelial markers we identi-
fied might normally be expressed during development
but are turned off in the adult, except during pathological
situations. One TEM that might have such an expression
pattern is doppel, a cell surface prion-like receptor previ-
ously found to be expressed in mouse brain endothelium
during development. Doppel expression levels peak with
maximal vessel proliferation 1 week after birth, but are un-
detectable by 8 weeks (Robertson et al., 1985; Li et al.,
2000). Consistent with these studies, we also failed to de-
tect doppel in normal adult brain. Apelin is another TEM
that was previously found to be expressed in developing
vessels (Saint-Geniez et al., 2002; Kasai et al., 2004;
Cox et al., 2006).
The most differentially expressed TEM identified by
SAGE, Vscp, encodes a previously uncharacterized cyto-
plasmic SH2-containing protein. We identified the com-
plete nucleotide sequence of Vscp and demonstrated the
selective expression of this gene in tumor endothelium.
However, evaluation of its potential as a therapeutic target
of tumor endothelium will require further studies including
the development of antibodies against the mouse and hu-
man VSCP protein. Seven of the remaining genes encode
cell surface proteins, making them appealing potential tar-
gets for tumor-specific vascular therapy. Four of these
genes are thought to be involved in regulating inflamma-
tory or autoimmune responses. These include CD276,
CD137, PTPRN, andCD109. The identification of immuno-
regulatory genes is not unexpected given that inflamma-
tory cells are typically present in tumors. However, these
genes were originally thought to be expressed only by
the activated inflammatory cells themselves and not by tu-
mor endothelium. One notable exception is CD137, which
Broll and coworkers recently found, using immunohisto-
chemical staining, to be highly expressed in the vessels
of multiple different tumor types, while expression in nor-
mal vessels and inflammatory cells was undetectable
(Broll et al., 2001). Although these results were initially un-
expected by the authors performing that study, they are
consistent with the expression patterns described here.
Remarkably, antibodies against CD137 have been used
to regress established tumors in a number of preclinical
studies (Melero et al., 1997; Mittler et al., 2004). These re-
sponses were originally presumed to occur as a result of
enhanced immunogenicity against the tumor cells. The
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The Endothelial Transcriptomeexpression of cell surface CD137 in tumor vessels sug-
gests that therapeuticCD137antibodiesmay alsomediate
their effects in part by directly targeting the newly formed
blood vessels. We found that tumor ECs overexpressed
two forms of CD137, one that is membrane bound and
one that is presumably secreted. Although the exact func-
tion of each of these forms is unclear, soluble CD137 is
thought to be antagonistic to the costimulatory activity of
membrane-bound CD137 on T cells. Thus, sCD137 se-
creted by tumor ECs may serve to reduce immune activity
against tumors. Conversely, the antitumor effects ob-
served using anti-CD137 antibodies could presumably
be a result of enhanced immunogenicity toward tumor
cells due to removal of antagonistic sCD137 produced
by tumor vessels. Soluble CD137 has been found to be el-
evated in the sera of patients with rheumatoid arthritis, an
autoimmune disease associatedwith aberrant angiogene-
sis (Michel et al., 1998). Our results suggest that sCD137
may also be elevated in solid tumors andmay thus provide
a useful surrogate marker of tumor angiogenesis.
As an initial step toward evaluating the therapeutic po-
tential of additional endothelial targets in humans, we
have begun by focusing on CD276, the most differentially
expressed cell surface tumor-specific endothelial marker
identified by SAGE in this study. CD276 is a recently iden-
tified member of the B7 family of immunoregulatory mole-
cules that can be induced on T cells, B cells, and dendritic
cells by a variety of inflammatory cytokines (Chapoval
et al., 2001; Steinberger et al., 2004). Although the expres-
sion of CD276 on such cells could potentially complicate
a vascular targeting approach, so far we have not been
able to detect CD276 protein on inflammatory cells in tu-
mors of mice or humans. In contrast, we did detect strong
consistent staining of the tumor vasculature in colon,
lung, breast, esophageal, and bladder cancers. Further-
more, in many of the tumors examined, we found CD276
protein was also overexpressed by the tumor cells them-
selves. In such cases, agents which target CD276 may
target both the tumor and stromal compartments simulta-
neously, thus resulting in an enhanced therapeutic effi-
cacy. That CD276 was undetectable in the angiogenic
vessels of the corpus luteum suggests that this might
be a particularly attractive candidate for future therapeutic
studies aimed at selectively targeting the tumor vas-
culature.
EXPERIMENTAL PROCEDURES
Tumor Tissues, Cell Lines, and Animal Studies
Anonymized human tissue samples were provided by the Cooperative
Human Tissue Network (CHTN), with approval from the NIH Office of
Human Subject Research. CHTN is funded by the National Cancer In-
stitute. EMT6 cells were a kind gift from Robert S. Kerbel, KM12SM
cells were a kind gift from Isaiah J. Fidler, HCT116 cells were from
the DCT tumor repository (NCI, Frederick), and LS174T, SW620,
CT26, and LLC were from the American Type Culture Collection (Man-
assas, VA). All tumor cell lines were maintained in DMEMmedium con-
taining 10% fetal bovine serum. Tumors were made by inoculating 53
105 to 1 3 106 cells either subcutaneously or intrasplenically. To pro-
duce liver metastasis by intrasplenic injection, the spleen was exterior-
ized through a left lateral incision prior to tumor cell injection. The tu-mor cell suspension was allowed to enter the portal circulation over
a period of 5 min, after which the spleen was removed. For 70% partial
hepatectomy, the liver was exposed through a midline abdominal inci-
sion, and the two anterior lobes were exteriorized and the suspensory
ligaments severed. The left lateral and caudal lobes were gently tied off
prior to excision and placement of the remaining liver back into the
peritoneal cavity. All animal experiments were performed in accor-
dance with NCI-Frederick ACUC guidelines.
Endothelial Cell Isolations
Immediately following CO2 euthanasia, normal or tumor tissues were
resected, diced with a razor, and then digested in Hepatocyte Wash
Buffer (Invitrogen, Carlsbad, CA) containing 2 mg/ml collagenase A
(Roche, Indianapolis, IN) for 1 hr at 37C. All subsequent steps were
performed on ice or at 4C. After filtering sequentially through 100 mm
and 25 mm mesh, cells were pelleted and rinsed repeatedly with
PBS containing 0.5% BSA (PBS/BSA) until the supernatant was trans-
parent. To remove hematopoietic cells from the sample, we incubated
cells with amixture of streptavidin-linked dynabeads (Dynal, Lake Suc-
cess, NY) that had been separately prebound to biotin anti-CD19, bi-
otin anti-CD45 (BD Pharmingen, San Diego, CA), or biotin anti-F480
(Caltag Laboratories, Burlingame, CA) and then mixed at a 1:1:1 ratio.
To prevent nonspecific binding of Fc-receptor containing cells in the
positive selection, anti-CD16/32 antibodies (Fc Block; BD Pharmin-
gen) were added to the cell suspension. For SAGE libraries, ECs
from heart, kidney, intestine, liver, lung, KM12SM tumors, and
LS174T tumors were labeled with biotinylated rat anti-mouse CD105
(eBioscience, San Diego, CA); to label ECs from spleen, CT26 tumors,
or LLC tumors, biotinylated goat anti-mouse VE-cadherin (R&D Sys-
tems, Minneapolis, MN) was added, and to label ECs from brain, mus-
cle, EMT6 tumors, and SW620, a mixture of both antibodies was
added. The selection markers used to isolate ECs for QPCR can be
found in Table S3. After rinsing five times with PBS/BSA, streptavi-
din-linked dynabeads were added to the cell suspension, rotated
5min at 4C, and diluted to 40ml with PBS/BSA, and bead-bound cells
were captured using a Dynal MPC-50 magnet. Captured ECs were
rinsed five to ten times until only bead-bound cells were observed.
Cells were resuspended in mRNA lysis/binding buffer for SAGE or
mRNA extraction buffer for RT-PCR. After removing the beads, lysates
were stored at 80C until ready to use.
Construction of SAGE Libraries
LongSAGE libraries were constructed using the I-SAGE Long Kit (Invi-
trogen) and our previously established MicroSAGE protocol (for
a detailed protocol see: http://www.sagenet.org/protocol/index.htm).
Ditags were PCR amplified using biotinylated primers to facilitate
efficient linker removal and Mme-I enzyme was purchased from New
England Biolabs (Ipswich, MA). The endothelial SAGE data has been
deposited into the SAGE Genie public database (http://cgap.nci.nih.
gov/SAGE).
Quantitative PCR
mRNA was purified using the Quick Prep Micro mRNA purification kit
(Amersham, Piscataway, NJ). Single-stranded cDNA was generated
using the Superscript III first strand synthesis system (Invitrogen) fol-
lowing the manufacturer’s directions. Quantitative PCR was per-
formed with an MX4000 using Brilliant SYBR Green QPCR Master
Mix, and threshold cycle numbers were obtained using MX4000 soft-
ware v. 4.20 (Stratagene, La Jolla, CA). Primer sets for each sequence
analyzed are included in Table S10. All primers were designed to span
large introns thereby preventing potential amplification of contaminat-
ing genomic DNA. Primers were only used if they produced a single
band of the expected size upon gel electrophoresis and failed to pro-
duce primer dimer products as assessed by gel electrophoresis and
melting point analysis on the MX4000. Conditions for amplification
were: one cycle of 95C, 10 min followed by 40 cycles of 95C, 20 s;
56C, 30 s; and 72C, 30 s. Quantitative PCRs were performed in du-
plicate, and threshold cycle numbers were averaged. Gene expressionCancer Cell 11, 539–554, June 2007 ª2007 Elsevier Inc. 549
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(A) Localization ofmRNA in tumor ECs (red stain) was demonstrated by examining apelin and doppel in subcutaneous implanted LLC tumors. Note the
lack of detectable expression in the normal brain and liver tissues of these representative TEMs.
(B) Localization of various TEMs in the tumor endothelium of mice. Depicted are CD137 in a KM12SM tumor from the liver, CD109 and MiRP2 in
SW620 subcutaneous tumors and CD276, PTPRN, ETSvg4, and Vscp in HCT116 subcutaneous tumors.
(C)CD276mRNA is expressed in the vessels of human colorectal cancer. In situ hybridization revealed thatCD276mRNA is expressed predominantly
in the vessels of human colorectal cancer (middle panel) with a pattern of staining similar to that of the control endothelial marker VEGFR2 (left panel).
Note that in the case ofCD276 the tumor cells also display positive staining, albeit less intense. At the margin between tumor (T) tissue and normal (N)550 Cancer Cell 11, 539–554, June 2007 ª2007 Elsevier Inc.
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pressed in Human Tumors
(A) Immunoblotting with anti-CD276 monoclo-
nal antibody revealed an upregulation of
CD276 protein in colorectal tumors, T, com-
pared to normal, N, colonic mucosa. Ten of
the paired samples represent matched tissues
taken from the same patient (P1–P10). CD276
protein migrates at a size similar to that ob-
served in 293 cells transfected with the 4IgG-
containing form of CD276 (293/CD276). The
faint product present in 293 parent cells pre-
sumably represents low-level endogenous
CD276 expression which can also be detected
at the mRNA level in these cells by RT-PCR
(data not shown).
(B) Immunoblotting with a CD276 monoclonal
antibody revealed an upregulation of CD276
protein in lung tumors, T, compared to normal,
N, adjacent lung tissue. The normal tissues in
(A) and (B) were classified as normal based
on grossmorphology, butmicroscopic disease
or inflammatory host cells may have contrib-
uted to the low level CD276 expression ob-
served in these tissues.
(C–L) Immunohistochemical staining with
a polyclonal CD276 antibody revealed a ves-
sel-like pattern (brown stain) in colorectal can-
cer (C–E), non-small-cell lung cancer (F–H),
esophageal cancer (I–J), bladder cancer (K),
and breast cancer (L). At the tumor margin (E)
CD276 staining was weak or undetectable in
normal colonic mucosa, N, but strong in the
vessels of the adjacent tumor region, T. Ves-
sels from normal tissues that failed to stain
for CD276 were immunoreactive on control se-
rial sections stained for endothelial proteins
such as vWF (data not shown). In some tumors,
the vessels appeared to stain most promi-
nently (C–E) and (H–K) whereas in others, both tumor cells and tumor vessels were strongly positive (F), (G), and (L). Note the strong cell surface stain-
ing pattern in the tumor epithelium under high powermagnification (G). Many of the blood vessels were readily identified by the presence of blood cells
in the lumen; for example see inset displaying higher power magnification of boxed region in (H). Sections were lightly counterstained with hematox-
ylin (blue stain). Scale bar, 50 mM.was normalized to that of the 70 Kd U1 small nuclear ribonucleoprotein
polypeptide A (Srnp70), a gene that is uniformly expressed in all ECs as
assessed by SAGE. Relative expression was calculated using the
equation 2(RtEt)/2(RnEn) where Rt is the threshold cycle number
observed in the experimental sample for Srnp70, Et is the threshold
cycle number observed in the experimental sample for the gene of
interest (GOI), Rn is the average threshold cycle number observed
for Srnp70 in all the N-EC samples, and En is the average threshold
cycle number observed for the GOI in all the N-EC samples.
In Situ Hybridization
Digoxigenin (DIG)-labeled antisense RNA probes were generated by
PCR amplification of 500–600 bp products incorporating T7 promoters
into the antisense primers. The primers used to generate riboprobes
can be obtained from the authors upon request. In vitro transcription
was performed with DIG RNA labeling reagents and T7 RNA polymer-
ase according to the manufacturer’s instructions (Roche). Tumors and
normal tissues were dissected, embedded in OCT, frozen in a dry ice-methanol bath, and cryosectioned at 10 mm. All sections were imme-
diately fixed with 4% paraformaldehyde, permeabilized with protein-
ase K, rinsed with 5X SSC, and incubated with RNA probes (100 ng/ml)
diluted in ISH solution (Dako, Carpinteria, CA) overnight at 55C.
After washing three times with 2 3 SSC, sections were incubated at
37C with RNase Cocktail (Ambion, Austin, TX) diluted 1:200 in 2 3
SSC. Slides were stringently washed twice in 23 SSC/50% deionized
formamide (American Bioanalytical, Natick, MA) and then once with
0.1 3 SSC at 55C. Before immunodetection, tissues were treated
with peroxidase blocking reagent (Dako) and blocked with 1% block-
ing reagent (Roche) containing purified, nonspecific rabbit immuno-
globulins (Dako). For signal amplification, a horseradish peroxidase-
rabbit anti-DIG antibody (Dako) was used to catalyze the deposition
of FITC-tyramide (GenPoint Fluorescein kit, Dako). Further amplifica-
tion was achieved by adding horseradish peroxidase-rabbit anti-
FITC (Dako), biotin-tyramide (GenPoint Kit, Dako), and then alkaline
phosphatase rabbit anti-biotin (Dako). Signal was detected with the al-
kaline phosphatase substrate Fast Red TR/Napthol AS-MX (Sigmacolonic mucosa CD276 staining abruptly ends (right panel). The red extracellular staining around the normal crypts represents nonspecific binding of
the in situ hybridization reagents to the mucous (right panel) and is also present in control sections (data not shown). A dilute blue counterstain was
applied to each of the sections. Scale bars, 50 mM.Cancer Cell 11, 539–554, June 2007 ª2007 Elsevier Inc. 551
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The Endothelial TranscriptomeChemical Co., St. Louis, MO). Cells were lightly counterstained with
hematoxylin and mounted with Aqueous Mounting Medium (BioGe-
nex, San Ramon, CA).
Immunohistochemistry
Paraffin sections were deparaffinized, incubated with proteinase K,
heated at 95C for 20 min in citrate buffer (pH6) (Invitrogen), and
treated with peroxidase blocking reagent (Dako). Sections were incu-
bated with a biotin-labeled polyclonal antibody against CD276 (R&D)
followed by an HRP-conjugated anti-biotin antibody (Dako) and visual-
ized by DAB (diaminobenzidine) staining. Sections were lightly coun-
terstained with hematoxylin.
Immunoblotting
A CD276 expression vector was made by excising a human CD276
cDNA from an EST (accession number BC7472032) using the restric-
tion enzymes EcoR1 and Not1 and cloning the fragment into the
same sites of the expression vector pcDNA3.1(+) (Invitrogen). Se-
quencing of the CD276/pcDNA3 vector revealed that it contained
a full length CD276 cDNA corresponding to transcript variant 1 (acces-
sion number NM_001024736). CD276/pcDNA3 was transfected into
293 cells using lipofectamine, and stable transfectants selected with
Geneticin. To generate extracts for Immunoblotting, colorectal tissues
stored at80Cwere thawed, diced with a razor, immediately homog-
Figure 6. Immunofluorescence Staining Reveals Colocaliza-
tion of CD276 with vWF in Human Colon Cancer
(A) CD276 (green) was expressed predominantly by the tumor vessels
of the colorectal cancer, but was also expressed at a lower level by the
tumor cells themselves. Expression of CD276 in normal colonic mu-
cosa was undetectable (top middle panel). As a control, vessels
were stained for vWF (Red) which colocalized with CD276 only in the
tumor sample. Scale bar, 100 mm.
(B) CD276 expression was undetectable in the angiogenic vessels of
the developing corpus luteum. Scale bar, 200 mm. Sections were coun-
terstained with DAPI (blue), which is shown in the left panels to high-
light the epithelial cells.552 Cancer Cell 11, 539–554, June 2007 ª2007 Elsevier Inc.enized in cold TNT buffer (50 mM Tris [pH 7.5], 75 mM NaCl, 1% triton
X-100 containing a cocktail of protease inhibitors [Roche]), and clari-
fied by centrifugation. Protein extracts from tissues or lysed 293 cells
were separated by SDS-PAGE and transferred to a PDVF membrane
(Millipore). Immunoblots were probed with a monoclonal anti-CD276
antibody (eBioscience) or an anti-actin antibody (Chemicon) followed
by an HRP-conjugated anti-mouse secondary antibody (Jackson)
and visualized using the ECL plus system (Amersham) according to
the supplier’s instructions. For CD137 detection, extracts were immu-
noprecipitated with goat anti-CD137 polyclonal antibodies (Sigma)
and protein G and detected by Immunoblotting with the same antibody
followed by an HRP-conjugated anti-goat F(ab’)2 antibody (Jackson).
Immunofluorescence
Dual-color immunofluorescence was performed on fresh-frozen sec-
tions fixed in Leukoperm (Serotec, Raleigh, NC). For CD105 detection,
sections were stained with rat anti-mouse CD105 followed by FITC-
linked goat-anti-rat (Jackson Immunoresearch Laboratories, West
Grove, PA) and 488 goat anti-FITC (Invitrogen). VE-cadherin was de-
tected using goat anti-mouse VE-cadherin followed by rhodamine-
streptavidin (Vector Laboratories, Burlingame, CA). For dual CD276
and vWF immunofluorescence staining of human colorectal sections,
we simultaneously stained tissues using a mouse anti-CD276 (R&D)
monoclonal antibody, and a rabbit anti-vWF polyclonal antibody
(DAKO). CD276 was detected with a FITC-conjugated goat anti-
mouse antibody (Jackson Immunoresearch Laboratories) followed
by a 488 goat-anti-FITC antibody (Invitrogen) and a 488 donkey anti-
goat antibody (Invitrogen). vWF was detected using a biotin-linked
donkey anti-rabbit antibody (Jackson Immunoresearch Laboratories)
followed by rhodamine-streptavidin (Vector Laboratories, Burlingame,
CA). Images were captured using a Nikon Eclipse E600 microscope.
Supplemental Data
The Supplemental Data include two supplemental figures and nine
supplemental tables and can be found with this article online at
http://www.cancercell.org/cgi/content/full/11/6/539/DC1/.
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